Candel Therapeutics (CADL) closed at $6.20 on November 13, 2026, down 26.1% from the previous close, on volume of 6,006,790 shares (30-day average 1,031,267).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
ACCESS Newswire (Fri, 13-Nov 3:42 PM ET)
Globe Newswire (Fri, 13-Nov 12:29 PM ET)
Candel Therapeutics Enters New $50 Million Stock Sale Agreement
TipRanks (Thu, 12-Nov 5:19 PM ET)
Candel Therapeutics GAAP EPS of -$0.28 beats by $0.07
Seeking Alpha News (Thu, 12-Nov 4:48 PM ET)
Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights
Globe Newswire (Thu, 12-Nov 4:05 PM ET)
Globe Newswire (Fri, 6-Nov 9:00 AM ET)
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Thu, 5-Nov 4:05 PM ET)
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Mon, 2-Nov 4:05 PM ET)
Globe Newswire (Thu, 29-Oct 9:00 AM ET)
Candel Therapeutics to Present at November Investor Conferences
Globe Newswire (Tue, 27-Oct 8:05 AM ET)
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Candel Therapeutics trades on the NASDAQ stock market under the symbol CADL.
As of November 13, 2026, CADL stock price declined to $6.20 with 6,006,790 million shares trading.
CADL has a beta of 0.96, meaning it tends to be less sensitive to market movements. CADL has a correlation of 0.02 to the broad based SPY ETF.
CADL has a market cap of $474.42 million. This is considered a Small Cap stock.
In the last 3 years, CADL traded as high as $14.60 and as low as $.77.
The top ETF exchange traded funds that CADL belongs to (by Net Assets): VTI, XBI, IWM, VXF, IWO.
CADL has outperformed the market in the last year with a return of +34.5%, while the SPY ETF gained +13.4%. However, in the most recent history, CADL shares have underperformed the stock market with its stock returning -47.5% in the last 3 month period and -25.6% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
CADL support price is $7.92 and resistance is $8.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CADL shares will trade within this expected range on the day.
